ALTITUDE-AD: Use of a Validated Plasma pTau217 Assay to Screen Potential Participants in an Ongoing Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Sabirnetug for Early Alzheimer’s Disease (S15.008)
To investigate using a plasma pTau217 assay to enrich the population of potential study participants with those likely to have brain amyloid burden sufficient for inclusion in a study of early symptomatic Alzheimer’s disease (AD).
Authors
- Michael E. Hyland (ORCID: https://orcid.org/0000-0003-3879-0469)
- H. Todd Feaster
- Vladimir Skljarevski
- Jasna Jerecı̀ć
- Eric Siemers
- June Kaplow
- Robert A. Dean
- Karen Sundell
- Gopalan Sethuraman
Institutions
- Acumen Pharmaceuticals (United States) (US)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000211295
- Citations
- 1
- Primary Topic
- Medicinal Plants and Bioactive Compounds
- Type
- article
- Field-Weighted Citation Impact
- 0.81